
Catherine Bollard MD
Professor, Pediatrics and Microbiology, Immunology and Tropical Medicine The George Washington University Director- Program for Cell Enhancement and Technologies for Immunotherapy Children's National Health System and Chief, Division of Allergy and Immunology CNHS
Join to View Full Profile
111 Michigan Ave NwWashington, DC 20010
Phone+1 202-476-4776
Fax+1 832-825-4247
Dr. Bollard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of Otago School of MedicineMD, Immunology, 2000 - 2005
- Registrar - HematologyFRCPA, Hematology, 1997 - 2002
- Registrar- PediatricsFRACP, Pediatrics, 1995 - 2002
- University of Otago School of MedicineClass of 1991
Certifications & Licensure
- DC State Medical License 2013 - 2027
- TX State Medical License 2004 - 2014
- Royal Australian College of PhysicansPediatrics and Child Health Division
- Royal College of Pathologists of AustraliaHematology and Immunology
Awards, Honors, & Recognition
- Induction into the Henry Kunkel Society 2014
- Basi Science Award European Group for Blood and Marrow Transplantation (EBMT), 2011
- Elected Member The American Society for Clinical Investigation, 2010
- Join now to see all
Clinical Trials
- Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease Start of enrollment: 1996 Jan 01
- LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma Start of enrollment: 2003 Sep 01
- Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD Start of enrollment: 2007 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Reconstitution of Norovirus-Specific T-Cell Responses Following Hematopoietic Stem Cell Transplantation in Patients With Inborn Errors of Immunity and Chronic Noroviru...Jessica Durkee-Shock, Ariella Cohen, Naseem Maghzian, Gloria Pezzella, Mariah Jensen-Wachspress
The Journal of Infectious Diseases. 2025-03-17 - T Cell Immune Response to Influenza Vaccination When Administered Prior to and Following Autologous Chimeric Antigen Receptor-Modified T Cell Therapy.Hannah Kinoshita, Carla S Walti, Kathleen Webber, Gloria Pezzella, Mariah Jensen-Wachspress
Transplantation and Cellular Therapy. 2025-03-01 - Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.Adetola A Kassim, Mark C Walters, Mary Eapen, Madoc Smith, Brent R Logan
NEJM Evidence. 2025-03-01
Journal Articles
- Management Guidelines for Paediatric Patients Receiving Chimeric Antigen Receptor T Cell TherapyKris M Mahadeo, Julie C Fitzgerald, Marie E Steiner, Partow Kebriaei, Katayoun Rezvani, Ira M Cheifetz, John M Slopis, Paul L Martin, Sattva S Neelapu, Agne Tarasevici..., Nature
- EBV/LMP-specific T Cells Maintain Remissions of T and B Cell EBV Lymphomas After Allogeneic Bone Marrow TransplantationStephen Gottschalk, Rayne Rouce, Catherine M Bollard, Malcolm K Brenner, Helen E Heslop, Blood
- Reduced Intensity Conditioning for Hematopoietic Cell Transplant for HLH and Primary Immune Deficiencies: BMT CTN 1204Shalini Shenoy, K Scott Baker, Elizabeth O Stenger, Mary Eapen, Carl Allen, Lauri Burroughs, Philip Roehrs, Catherine M Bollard, Rabi Hanna, Jeffrey R Andolina, James ..., Blood
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Identifying Novel Immunodominant Epitopes within Human Parainfluenza Virus-3 Matrix ProteinCatherine M. Bollard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCHCatherine M. Bollard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Ultra low-dose il-2 mediated expansion of regulatory T cells as GVHD prophylaxis for recipients of allogeneic hematopoietic stem cells blood transplantation.Catherine Bollard 1,*,Alana Kennedy-Nasser 2,A. John Barrett 3,Sawa Ito 3,Eric Yvon 4,Robert Krance 2,Kathryn Leung 2,Helen E. Heslop 2,Malcolm K. Brenner2, Poster Presentation, EBMT; Bone Marrow Transplant, Milan, Italy, 1/31/2014
- Join now to see all
Lectures
- Optimizing Clinical Outcomes in Blood Cancers Through Groundbreaking Translational Research61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Meet the Blood Editors60th American Society of Hematology Annual Meeting - 12/3/2018
- Meet the Blood Editors60th American Society of Hematology Annual Meeting - 12/1/2018
- Join now to see all
Other
- "Ask the Doctor About Lymphoma" ProgramHouston Chapter of the Lymphoma Research Foundation
Houston, TX - 1/24/2009 - Pac-Man' cancer treatment underway in Houston.ABC Channel 13
http://abclocal.go.com/ktrk/video?id=7174696
1/16/2009 - Leukemia Lymphoma Society enews line
http://www.leukemia-lymphoma.org/eMarketing/eNewsArchives/eNewsline/2009/March.htm
1/1/2009 - Join now to see all
Press Mentions
- Catherine Bollard, MBChB, MD, Appointed Senior Vice President and Chief Research OfficerFebruary 19th, 2025
- Children’s National Hospital and Virginia Tech Expand Research Partnership to Advance Pediatric HealthFebruary 5th, 2025
- Cutting Edge Advancements in Regenerative Medicine Takes Centerstage at 2nd Annual ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2024October 28th, 2024
- Join now to see all
Grant Support
- Anti-Viral And Antileukemic T-Cell Therapy As Prophylaxis After HSCTNational Heart, Lung, And Blood Institute2011
- Clinical Trial: The Administration Of Neomycin Resistance Gene Marked EBV SpeciNational Center For Research Resources2011
- Clinical Trial: Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes ForNational Center For Research Resources2011
- Adoptive Transfer Of Cord Blood T Cells To Prevent And Treat CMV And AdenovirusNational Center For Research Resources2011
- Improving Cord Blood TransplantationNational Cancer Institute2011
- Enhancing Treg Immune Reconstitution After Stem Cell TransplantNational Cancer Institute2011
- Administration Of Tgf-B Resistant Lmp2a-Specific Cytotoxic T-Lymphocytes To PNational Center For Research Resources2010–2011
- Clinical Trial: Virus Specific Cytotoxic T-Lymphocytes For The Prophylaxis Of CMNational Center For Research Resources2008–2011
- Clinical Trial: Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes For ENational Center For Research Resources2008–2010
- Clinical Trial: Administration Of Virus-Specific Cytotoxic T-Lymphocytes For TheNational Center For Research Resources2008–2010
- Clinical Trial: Administration Of Neomycin Resistance Gene Marked EBV Specific CNational Center For Research Resources2008–2009
- Clinical Trial: Administration Of Lmp2a-Specific Cytotoxic T-Lymphocytes FollowNational Center For Research Resources2008
- Administration Of Virus-Specific Cytotoxic T-Lymphocytes For The ProphylaxisNational Center For Research Resources2007
- Administration Of Lmp2a-Specific Cytotoxic T-Lymphocytes Following CD45 AntiNational Center For Research Resources2006–2007
- Virus Specific Cytotoxic T-Lymphocytes For The Prophylaxis Of CMVNational Center For Research Resources2005–2007
- Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes For EBV Pos LymphomaNational Center For Research Resources2005–2007
- Administration Of Lmp2a-Specific Cytotoxic T-Lymphocytes Following CD45National Center For Research Resources2005
- Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes For EBV Pos. LymphomaNational Center For Research Resources2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: